In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
News|Articles|October 24, 2023
Kiromic BioPharma, Beverly Hills Cancer Center to Partner on Clinical Trials
Treatment facility to be the first to evaluate Deltacel for patients with non-small cell lung cancer.
Advertisement
Kiromic BioPharma announced that it has agreed to terms for Beverly Hills Cancer Center (BHCC) to serve as the inaugural clinical site for the evaluation of Deltacel (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, gamma delta t-cell (GDT) therapy, in patients with non-small cell lung cancer. BHCC includes a radiation oncology center, an infusion center, a full-service diagnostic imaging center (featuring MRI, CT, PET/CT), a diagnostic laboratory, and has previously conducted multiple clinical trials across multiple cancer types.
“As our clinical research program embarks on this groundbreaking clinical journey, we envision a future where patients have access to pioneering therapies and renewed hope in their battle against cancer. For years, BHCC has remained at the forefront of medical excellence, continually seeking innovative approaches to redefine the future of cancer treatment. We are very excited about this collaboration with Kiromic, a very forward-thinking and innovative company, and about this new therapeutic approach and the potential to contribute to science with the ultimate goal of improving the lives of cancer patients worldwide,” said Afshin Eli Gabayan, MD, medical director, principal investigator, Beverly Hills Cancer Center and Assistant Clinical Professor at UCLA-David Geffen School of Medicine.
Reference: Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement. BusinessWire. October 23, 2023. Accessed October 23, 2023. https://www.businesswire.com/news/home/20231023260123/en/Kiromic-BioPharma-and-Beverly-Hills-Cancer-Center-Enter-Clinical-Trial-Agreement
Advertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Where AI Governance in Clinical Development Falls Short
4
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
5